Our IP practice provides analysis, assessment and advice on life science IP. The practice is focussed on both helping clients extract maximum value from their IP portfolios and supporting companies and investors conducting IP due diligence.
The service is designed to sit alongside that offered by established patent firms. Alacrita does not file and maintain patents but rather provides high level strategic advice. For example, patent applications and procedures can take on a life of their own, with organisational inertia masking the need for a decision. Alacrita can provide a realistic, commercially relevant reality check, helping clients rationalise and prioritise IP assets.
The practice is led by a European and Chartered Patent Attorney who has worked in Intellectual Property since 1983 and was a Partner in a patent attorney firm from 1988 to 2009. His technical areas of expertise span pharmaceutical chemistry, pharmacology, microbiology, biotechnology, genetic engineering, stem cells, physiology, pharmacogenomics, proteomics, plant and animal protection, medtech and medical instruments.
Our US patent attorney has spent time working in-house in a number of biotechnology companies, having served as Patent Examiner with the United States Patent and Trademark Office.
Alacrita’s patent information analyst has over 20 years experience at GlaxoSmithKline and as an independent consultant. Through the provision of patent searches for novelty, patentability, validity, freedom to operate as well as product patent positions, she supports patent agents in subject areas such as pharmacology, formulations, drug delivery, vaccines, biomedicine, biotechnology, pharmacogenomics, biomarkers and diagnostics.